MK-1484 for Advanced or Metastatic Solid Tumors

Phase-Based Progress Estimates
Erasmus Medisch Centrum-Medical Oncology ( Site 0036), Rotterdam, Netherlands
Advanced or Metastatic Solid Tumors+1 More
Pembrolizumab - Biological
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.

Eligible Conditions

  • Advanced or Metastatic Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Advanced or Metastatic Solid Tumors

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: Up to approximately 27 months

Month 24
Area Under the Curve (AUC) of MK-1484
Maximum Serum Concentration (Cmax) of MK-1484
Minimum Serum Concentration (Cmin) of MK-1484
Day 21
Number of Participants with a Dose-Limiting Toxicity (DLT) Graded Using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 5.0
Month 24
Number of Participants Who Discontinue Study Treatment Due to an AE
Month 27
Number of Participants Who Experience At Least One AE

Trial Safety

Safety Progress

1 of 3

Other trials for Advanced or Metastatic Solid Tumors

Trial Design

2 Treatment Groups

1 of 2
MK-1484 + Pembrolizumab
1 of 2
Experimental Treatment

70 Total Participants · 2 Treatment Groups

Primary Treatment: MK-1484 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: MK-1484 · Intervention Types: Biological
MK-1484 + PembrolizumabExperimental Group · 2 Interventions: Pembrolizumab, MK-1484 · Intervention Types: Biological, Biological
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 27 months
Closest Location: Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011) · Toronto, Canada
Photo of Toronto  1Photo of Toronto  2Photo of Toronto  3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Advanced or Metastatic Solid Tumors
0 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.